HCA · Insider Trading
HCA Healthcare, Inc.
Every open-market purchase and sale reported by HCA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | J | −7,769 | −$3.33M |
| 2026-05-11 | Mike A Marks | EVP and CFO | G | — | — |
| 2026-04-30 | John Chidsey | Director | A | +809 | — |
| 2026-04-30 | Nancy Ann Deparle | Director | A | +509 | — |
| 2026-04-30 | Hugh F Johnston | Director | A | +809 | — |
| 2026-04-30 | Michael W Michelson | Director | A | +925 | — |
| 2026-04-30 | Wayne Joseph Riley | Director | A | +509 | — |
| 2026-04-30 | Andrea B Smith | Director | A | +509 | — |
| 2026-04-30 | Thomas F Frist III | Director | A | +1,041 | — |
| 2026-04-30 | William R Frist | Director | A | +809 | — |
| 2026-02-18 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | MIXED | — | −$1.51M |
| 2026-02-12 | Jennifer Berres | SVP & Chief Human Res. Officer | MIXED | −3,419 | −$5.39M |
| 2026-02-12 | Michael S. Cuffe | EVP and Chief Clinical Officer | MIXED | +6,127 | −$1.76M |
| 2026-02-12 | Jon M Foster | EVP and COO | MIXED | +9,808 | −$2.96M |
| 2026-02-12 | Samuel N Hazen | CEO | MIXED | +33,611 | −$10.71M |
| 2026-02-12 | Mike A Marks | EVP and CFO | MIXED | +3,336 | −$848.46K |
| 2026-02-12 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | MIXED | +5,366 | −$1.51M |
| 2026-02-12 | Erica Rossitto | SVP & Chief Nurse Executive | MIXED | +1,258 | −$209.86K |
| 2026-02-12 | Christopher F. Wyatt | SVP & Controller | MIXED | −1,684 | −$2.54M |
| 2026-02-10 | Frisco Holding II | 10%+ Owner | J | −72,047 | — |
| 2026-02-10 | HERCULES HOLDING II | 10%+ Owner | J | −36,629,188 | — |
| 2026-02-10 | Patricia F Elcan | 10%+ Owner | J | −72,047 | — |
| 2026-02-10 | Thomas F Frist III | Director | J | −72,047 | — |
| 2026-02-10 | William R Frist | Director | J | −72,047 | — |
| 2026-02-10 | Thomas F Frist Jr | 10%+ Owner | J | −72,047 | — |
| 2026-02-09 | Jon M Foster | EVP and COO | MIXED | +13,254 | −$4.18M |
| 2026-02-09 | Christopher F. Wyatt | SVP & Controller | MIXED | +4,996 | −$1.43M |
| 2026-02-05 | Michael S. Cuffe | EVP and Chief Clinical Officer | MIXED | −5,550 | −$747.14K |
| 2026-02-05 | Samuel N Hazen | CEO | MIXED | −42,877 | −$21.48M |
| 2026-02-02 | Jennifer Berres | SVP & Chief Human Res. Officer | A | +6,206 deriv. | — |
| 2026-02-02 | Michael S. Cuffe | EVP and Chief Clinical Officer | A | +8,067 deriv. | — |
| 2026-02-02 | Jon M Foster | EVP and COO | A | — | — |
| 2026-02-02 | Samuel N Hazen | CEO | MIXED | +42,877 | −$13.34M |
| 2026-02-02 | Mike A Marks | EVP and CFO | A | +11,945 deriv. | — |
| 2026-02-02 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | A | +8,067 deriv. | — |
| 2026-02-02 | Christopher F. Wyatt | SVP & Controller | A | +2,560 deriv. | — |
| 2025-11-18 | Samuel N Hazen | CEO | G | −14,830 | — |
| 2025-11-05 | Mike A Marks | EVP and CFO | G | −165 | — |
| 2025-11-05 | Michael R McAlevey | EVP & Chief Legal & Admin Off. | MIXED | — | −$3.01M |
| 2025-11-04 | Samuel N Hazen | CEO | MIXED | +29,877 | −$8.91M |
| 2025-09-08 | Michael S. Cuffe | EVP and Chief Clinical Officer | MIXED | — | −$2.63M |
| 2025-07-31 | John Chidsey | Director | A | +496 | — |
| 2025-05-15 | Jon M Foster | EVP and COO | MIXED | −15,698 | −$5.80M |
| 2025-05-15 | Samuel N Hazen | CEO | G | — | — |
| 2025-05-08 | Mike A Marks | EVP and CFO | MIXED | −288 | −$0 |
| 2025-05-01 | Robert J Dennis | Director | A | +1,026 | — |
| 2025-05-01 | Nancy Ann Deparle | Director | A | +645 | — |
| 2025-05-01 | Hugh F Johnston | Director | A | +1,026 | — |
| 2025-05-01 | Michael W Michelson | Director | A | +1,173 | — |
| 2025-05-01 | Wayne Joseph Riley | Director | A | +645 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Patricia F Elcan | 10%+ Owner | 32,323,941 | $15.11B |
| HERCULES HOLDING II | 10%+ Owner | 32,282,889 | $15.09B |
| Thomas F Frist Jr | 10%+ Owner | 478,955 | $223.82M |
| Samuel N Hazen | CEO | 81,573 | $38.12M |
| Erol R Akdamar | Group President | 80,000 | $37.38M |
| Phillip G Billington | SVP-Internal Audit Services | 52,702 | $24.63M |
| Christopher F. Wyatt | SVP & Controller | 48,379 | $22.61M |
| Mike A Marks | EVP and CFO | 46,576 | $21.77M |
| Jon M Foster | EVP and COO | 40,516 | $18.93M |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 35,580 | $16.63M |
| Robert J Dennis | Director | 26,601 | $12.43M |
| Nancy Ann Deparle | Director | 21,910 | $10.24M |
| Thomas F Frist III | Director | 15,858 | $7.41M |
| William R Frist | Director | 15,156 | $7.08M |
| Wayne Joseph Riley | Director | 15,029 | $7.02M |
| Michael W Michelson | Director | 12,576 | $5.88M |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11,993 | $5.60M |
| Sammie S Mosier | SVP & Chief Nurse Executive | 11,113 | $5.19M |
| Erica Rossitto | SVP & Chief Nurse Executive | 10,407 | $4.86M |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 9,454 | $4.42M |
| Michael R McAlevey | EVP & Chief Legal & Admin Off. | 8,853 | $4.14M |
| Andrea B Smith | Director | 4,748 | $2.22M |
| Hugh F Johnston | Director | 4,475 | $2.09M |
| John Chidsey | Director | 1,308 | $611.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HCA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.